SNAP

• Research type

  Research Study

• Full title

  Staphylococcus aureus Network Adaptive Platform trial (SNAP)

• IRAS ID

  1005342

• Contact name

  Anna Goodman

• Contact email

  anna.goodman@gstt.nhs.uk

• Sponsor organisation

  University College London

• Eudract number

  2022-001238-13

• Clinicaltrials.gov Identifier

  NCT05137119

• Research summary

  Bacteraemia is a dangerous condition occurring when bacteria enter someone’s blood (infection in the blood). Bacteria called Staphylococcus aureus (S. aureus) can cause S. aureus bacteraemia (SAB). Up to a third of people with SAB die within three months, even when treated with antibiotics. The aim of the research is to find out which treatments for this illness are best and if we can reduce the number of deaths from this disease.
  To work out which medicine is best researchers use clinical trials called a randomised controlled trial (RCT). The treatments are chosen randomly (like the flip of a coin) and one person may receive more than one treatment. Some patients then receive one or more medicines, whilst other patients receive different treatment(s). This means the same patient can be in more than one part of the trial. In this trial the drugs used are already licensed drugs used around the world to treat patients with this disease.
  The sort of questions we want to answer are:
  1. What is the best main antibiotic treatment for S. aureus bacteraemia? This is being explored in a part of the trial (domain) called the 'backbone' (or main) antibiotic.
  2. Would it be better to add an extra antibiotic to treat the condition? This domain is called Adjunctive (additional) antibiotic(s).
  3. Once patients are feeling better do we need to continue antibiotics via a drip (usually in hospital) or could we give patients tablet antibiotics to take at home instead? This domain is called 'early oral switch' where some people are moved to tablet antibiotic(s) early.
  This is an international adaptive study so the researchers analyse the results as the study goes on rather than just at the end. If the results show any of the treatments do not work as well as others, they will be removed from the study. Similarly new arms may be added. The initial length of the trial is 4 and a half years. Each person would be in the trial for 3 months with their data collected & stored longer.

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  23/LO/0033

• Date of REC Opinion

  30 Aug 2023

• REC opinion

  Further Information Favourable Opinion